Study participants who took Zepbound also achieved remission or mild obstructive sleep apnea at a greater proportion than the placebo group. These results were observed among those who do and do ...

The sleep disorder also appears to have direct effects on brain health, a new study shows. People with sleep apnea appear to experience ... compared to 28% who had mild sleep problems and 16% ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Sleep apnea disrupts breathing during sleep. This can lead to Type 2 diabetes. Millions suffer from sleep apnea. The link between these conditions is often overlooked. Sleep studies diagnose sleep ...

Dec. 20, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with ...

A common sleep disorder ... approved to treat OSA. The FDA’s decision was informed by data from the SURMOUNT-OSA Phase III trials (NCT05412004). These studies evaluated Zepbound’s ...

42% of adults on Zepbound and 50% of adults on Zepbound with PAP therapy experienced remission or mild, non-symptomatic obstructive sleep apnea, compared to 16% and 14% of people who took the ...